Table 1. Comparison of the variable distribution and completeness in the entire and analytic datasets for hypertension among persons living with HIV—Zambia, 2021.
| Variable | Entire dataset, n (%) | Analytic dataset, n (%) | p-value |
|---|---|---|---|
| (N = 1,236,040) | (N = 101,363) | ||
| Sex | |||
| Female | 781,829 (63.3) | 65,570 (64.7) | <0.01 |
| Male | 454,211 (36.7) | 35,793 (35.3) | |
| Age group | |||
| 18–29 years | 232,099 (18.8) | 16,191 (16.0) | <0.01 |
| 30–44 years | 585,455 (47.4) | 45,850 (45.2) | |
| 45–59 years | 350,092 (28.3) | 32,681 (32.2) | |
| ≥60 years | 68,394 (5.5) | 6,641 (6.6) | |
| Province | |||
| Central | 125,704 (10.2) | 2,813 (2.8) | <0.01 |
| Copperbelt | 238,609 (19.3) | 7,197 (7.1) | |
| Eastern | 105,595 (8.5) | 3,672 (3.6) | |
| Luapula | 55,168 (4.5) | 54.0 (0.1) | |
| Lusaka | 343,981 (27.8) | 45,414 (44.8) | |
| Muchinga | 32,978 (2.7) | 512 (0.5) | |
| Northern | 52,014 (4.2) | 58.0 (0.1) | |
| Northwestern | 36,016 (2.9) | 1,893 (1.9) | |
| Southern | 128,299 (10.4) | 35,082 (34.6) | |
| Western | 91,156 (7.4) | 4,120 (4.1) | |
| Missing | 26,520 (2.1) | 548 (0.5) | |
| Urban/rural designation | |||
| Rural | 387,472 (31.3) | 18,454 (18.2) | <0.01 |
| Urban | 736,921 (59.6) | 78,123 (77.1) | |
| Missing | 111,647 (9.0) | 4,786 (4.7) | |
| Years on ART | |||
| 0–1 | 340,014 (27.5) | 19,087 (18.8) | <0.01 |
| 2–4 | 419,400 (33.9) | 28,182 (27.8) | |
| 5–9 | 301,575 (24.4) | 32,408 (32.0) | |
| ≥10 | 175,051 (14.2) | 21,686 (21.4) | |
| Current ART regimen | |||
| Efavirenz-based | 49,083 (4.0) | 1,423 (1.4) | <0.01 |
| Dolutegravir-based | 1,137,837 (92.1) | 97,049 (95.7) | |
| Both efavirenz and dolutegravir listed | 3,291 (0.3) | 133 (0.1) | |
| Other | 45,829 (3.7) | 2,758 (2.7) | |
| Most recent ART prescription length | |||
| <3 months | 141,776 (11.5) | 6,275 (6.2) | <0.01 |
| 3–5 months | 373,549 (30.2) | 27,839 (27.5) | |
| 6+ months | 720,706 (58.3) | 67,249 (66.3) | |
| Missing | 9.00 (0.0) | 0 (0.0) | |
| Body mass index (kg/m 2 ) | |||
| Normal (18.5–24.9) | 336,236 (27.2) | 51,056 (50.4) | <0.01 |
| Low (<18.5) | 59,860 (4.8) | 8,776 (8.7) | |
| Overweight (25.0–29.9) | 107,253 (8.7) | 19,668 (19.4) | |
| Obesity (≥30.0) | 53,674 (4.3) | 10,585 (10.4) | |
| Missing | 679,017 (54.9) | 11,278 (11.1) | |
| Initial CD4+ count (cells/mm 3 ) | |||
| 0–200 | 62,431 (5.1) | 7,694 (7.6) | <0.01 |
| 201–350 | 61,544 (5.0) | 7,195 (7.1) | |
| >350 | 107,473 (8.7) | 12,847 (12.7) | |
| Missing | 100,4592 (81.3) | 73,627 (72.6) | |
| Most recent CD4+ count (cells/mm 3 ) * | |||
| 0–200 | 59,590 (4.8) | 6,994 (6.9) | <0.01 |
| 201–350 | 101,297 (8.2) | 12,567 (12.4) | |
| >350 | 369,859 (29.9) | 49,690 (49.0) | |
| Missing | 705,294 (57.1) | 32,112 (31.7) | |
| Most recent viral load (copies/mL) † | |||
| <1000 | 975,952 (79.0) | 92,115 (90.9) | <0.01 |
| 1,000–9,999 | 16,881 (1.4) | 1,494 (1.5) | |
| ≥10,000 | 26,338 (2.1) | 2,595 (2.6) | |
| Missing | 216,869 (17.5) | 5,159 (5.1) | |
| Most recent creatinine ‡ | |||
| Normal | 36,457 (2.9) | 8,892 (8.8) | <0.01 |
| High | 5,829 (0.5) | 1,254 (1.2) | |
| Missing | 119,3754 (96.6) | 91,217 (90.0) | |
| Data capture at point-of-care | |||
| Paper-based with retrospective input | 495,498 (40.1) | 73,406 (72.4) | <0.01 |
| Direct electronic input | 552,109 (44.7) | 17,197 (17.0) | |
| Missing | 188,433 (15.2) | 10,760 (10.6) |
Variables are based on data from the most recent patient interaction in the electronic health record.
* 38.9% of recent CD4+ count measurements were from 2020 or 2021.
† 98.4% of recent viral load measurements were from 2020 or 2021.
‡ Elevated creatinine defined as ≥115 μmol/L in men and ≥98 μmol/L in women.
ART: Antiretroviral therapy.